Share CERo Therapeutics Announces Activation of the University of California, Davis as a Clinical Trial Site for the Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies

GlobeNewsWire · CERO · October 26, 2026

CERo Therapeutics Announces Activation of the University of California, Davis as a Clinical Trial Site for the Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies

Stocks To Buy Now app

Get the app for more

Explore stock news, insights and company research.

Get the app →
Source: GlobeNewsWire ↗